Antifibrotic effects of cyclosporine A on TGF‐β1–treated lung fibroblasts and lungs from bleomycin‐treated mice: role of hypoxia‐inducible factor‐1α
| Autor: | Koichiro Tatsumi, Risa Yamazaki, Hiroki Umezawa, Hiroyuki Nakamura, Ichiro Yoshino, Toshihiko Murayama, Yoshitoshi Kasuya, Tetsuo Fujita, Madoka Yanagihara |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine Pathology medicine.medical_specialty Pulmonary Fibrosis Chronic Lung Disorder Bleomycin Biochemistry Cell Line Transforming Growth Factor beta1 Mice 03 medical and health sciences Idiopathic pulmonary fibrosis chemistry.chemical_compound 0302 clinical medicine Pulmonary fibrosis Genetics medicine Animals Humans Lung Molecular Biology Fibroblastic foci business.industry Fibroblasts respiratory system Hypoxia-Inducible Factor 1 alpha Subunit medicine.disease respiratory tract diseases Mice Inbred C57BL 030104 developmental biology medicine.anatomical_structure chemistry Hypoxia-inducible factors 030220 oncology & carcinogenesis Cyclosporine business Immunosuppressive Agents Biotechnology Transforming growth factor |
| Zdroj: | The FASEB Journal. 31:3359-3371 |
| ISSN: | 1530-6860 0892-6638 |
| DOI: | 10.1096/fj.201601357r |
| Popis: | Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder that is characterized by aberrant tissue remodeling and the formation of fibroblastic foci that are composed of fibrogenic myofibroblasts. TGF-β1 is one of the factors that are responsible for fibrosis as it promotes fibroblast to myofibroblast differentiation (FMD) and is associated with up-regulation of α-smooth muscle actin. Therefore, inhibition of FMD may represent an effective strategy for the treatment of IPF. Here, we describe the treatment of human lung fibroblasts (WI-38 and HFL-1 cells) with cyclosporine A (CsA), which reduces TGF-β1-induced FMD |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text